Antimicrobial resistance development represents a major concern for both human and animal health. Ensuring effective treatments for infectious disease remains among the top concerns for physicians and veterinarians. Finding safe and effective therapeutic interventions that do not propagate resistance is key for sustaining adequate health care for humans and animals.

The search for appropriate therapeutic interventions extends well beyond simply finding new antibiotics. The future solutions will depend on new innovative technologies.

The development and commercialisation of these novel technologies are inherently more difficult and risky for the animal health industry to pursue.

Some of this risk lies in the regulatory environment in which these new technologies will be evaluated. The U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA/CVM) has developed a new approach to the development and evaluation of novel technologies intended for use as animal drugs. This presentation will discuss the efforts underway by FDA/CVM to meet the challenges presented with these novel technologies.